Small Stocks, Big Money

Foremost Clean Energy Ltd. (Nasdaq: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/FMST to learn more.

FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity. The company develops and markets enterprise-class software solutions—including Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), and Network Monitoring Services (NMS)—that enable customers to unify, secure, and optimize their digital infrastructure across cloud, hybrid, and on-premise environments.FatPipe serves over 2,500 end-user customers worldwide across sectors such as government, healthcare, finance, education, and retail, with its largest customer bases in the U.S. and India. The company’s patented technology allows for intelligent traffic failover, enhanced security, simplified network management, and deep observability—all delivered through a flexible, subscription-based model. For the fiscal year ended March 31, 2024, FatPipe generated $17.9 million in revenue and $4.4 million in net income—reflecting a strong 24.4% net margin.FatPipe is a client of RedChip. Visit RedChip.com to learn more.

BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.

Liberty Star Minerals (OTCQB: LBSR) is a U.S.-based mineral exploration company focused on advancing high-potential copper and gold projects in Arizona’s premier mining districts. The company’s flagship assets include the Red Rock Canyon Gold Project, a rapidly emerging high-grade epithermal gold discovery, and the Hay Mountain Project, a large-scale copper-gold porphyry target with confirmed mineralization. With recent bonanza-grade gold assays at Red Rock Canyon and first-ever drilling validating Hay Mountain’s porphyry potential, Liberty Star is strategically positioned for significant value creation. The company is actively seeking a joint venture partnership to accelerate development while leveraging strong exploration results and a favorable commodities market.Visit www.redchip.com/stocks/lbsr to learn more.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is prioritizing metastatic breast cancer, a setting with limited effective therapies and high unmet need, where (Z)-endoxifen has demonstrated encouraging clinical activity and favorable tolerability. This focus may enable a more efficient regulatory pathway while building a foundation for expansion into prevention, neoadjuvant, and adjuvant settings. With multiple ongoing Phase 2 trials, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Visit RedChip.com to learn more.

ConnectM Technology Solutions (Nasdaq: CNTM) is enabling a faster, smarter transition to an all-electric future through its AI-driven energy intelligence platform. The company integrates electrified energy assets with proprietary technology solutions, enabling residential, commercial, and transportation customers to efficiently transition from fossil fuels to renewable energy sources. With 120,000+ connected assets and growing, ConnectM is uniquely positioned in the rapidly expanding $2 trillion electrification market. Operating across Building Electrification, Distributed Energy, and Transportation & Logistics segments, ConnectM provides high-margin, scalable solutions, including AI-powered heat pumps, EV solutions, and smart energy management. Backed by a history of 20 consecutive quarters of revenue growth, a vertically integrated service network, and a first-mover advantage, ConnectM proving that an electrified economy is profitable.ConnectM Technology is a client of RedChip. Visit www.redchip.com/stocks/cntm to learn more.

bioAffinity Technologies (Nasdaq: BIAF) addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis and broad-spectrum cancer treatments. Lung cancer is the leading cause of cancer-related deaths. The Company’s first product, CyPath® Lung, improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. CyPath® Lung, a laboratory developed test (LTD), is patient-friendly and physician focused. Physicians order CyPath® Lung for their patients after lung cancer screening or other imaging reveals a suspicious finding.Patients collect their sample at home and ship overnight in a pre-paid envelope to the Company’s commercial laboratory, Precision Pathology Laboratory Services, where data is collected using flow cytometry. Proprietary automated data analysis, developed using artificial intelligence (AI), detects lung cancer by analyzing the lung microenvironment to identify cell populations that indicate malignancy. CyPath® Lung has shown high sensitivity (92%), high specificity (87%) and high accuracy (88%) in detecting early-stage lung cancer in patients with small pulmonary nodules less than 20 millimeters. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology.bioAffinity is a client of RedChip. Visit www.redchip.com/stocks/BIAF to learn more.

Connect Biopharma Holdings Ltd. (Nasdaq: CNTB) is a clinical-stage biotechnology company advancing innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company’s lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)—markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase 2 study demonstrating superior efficacy, rapid onset of action, and a favorable safety profile, Connect is strategically positioned to enter clinical trials targeting acute exacerbations in respiratory diseases, an area of significant unmet medical need. With a newly strengthened U.S.-based management team experienced in successful drug development and regulatory execution, including having collectively received FDA marketing approval for 16 therapeutic products, and with deep expertise in business development, corporate strategy, finance and operations, Connect Biopharma is uniquely positioned for substantial growth as it moves toward pivotal clinical milestones and commercialization.Connect Biopharma is a client of RedChip. Visit www.redchip.com/stocks/cntb to learn more.

BullFrog AI, a US-company headquartered in Maryland, is revolutionizing drug discovery and development with BullFrog Data Networks®, a cutting-edge platform powered by its proprietary bfLEAP® technology. Designed for small and mid-sized biopharma companies, BullFrog Data Networks® enables users to harness high-dimensional, multi-modal datasets, uncovering hidden relationships and pathways to accelerate target identification, clinical trial optimization, and drug repurposing. By providing affordable, AI-powered insights, BullFrog AI enhances decision-making and efficiency across the industry—helping resource-constrained organizations do more with less while enabling larger enterprises to optimize R&D investments and streamline drug development. In addition to driving growth through its Data Networks platform, BullFrog AI continues to advance its portfolio of licensed drug assets and partnerships with world-class research institutions like the J. Craig Venter Institute and the Lieber Institute for Brain Development.Bullfrog AI is a client of RedChip. Visit RedChip.com/stocks/BFRG to learn more.

Headquartered in Los Angeles, CA, LiveOne (Nasdaq: LVO) is an award-winning, creator-first, music, entertainment, and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. LiveOne's subsidiaries include Slacker Radio, PodcastOne (Nasdaq: PODC), PPVOne, CPS, LiveXLive, DayOne Music Publishing, Drumify and Splitmind. LiveOne is available on iOS, Android, Roku, Apple TV, Spotify, Samsung, Amazon Fire, Android TV, and through STIRR's OTT applications.LiveOne is a client of RedChip. Visit www.redchip.com/stocks/LVO to learn more.

Nexalin Technology is a pioneering medical technology company focused on addressing the global mental health crisis through innovative neurostimulation devices. Nexalin's products, which include the Gen-2 and newly introduced Gen-3 HALO™ Clarity devices, are non-invasive and utilize advanced frequency-based stimulation to target deep brain structures associated with various mental health disorders. These disorders include but are not limited to depression, anxiety, insomnia, PTSD, and traumatic brain injuries. Nexalin's commitment to non- pharmacological treatment options is underpinned by extensive clinical research and intellectual property protections, aiming to provide significant therapeutic benefits without adverse effects. The company's approach integrates product innovation with a virtual clinic model to enhance accessibility and effectiveness of treatments, offering a significant step forward in mental healthcare.Nexalin Technology is a client of RedChip. Visit RedChip.com to learn more.

Knightscope (Nasdaq: KSCP) is transforming public safety with cutting-edge robotics and AI technologies. From autonomous security robots to advanced detection systems, Knightscope is committed to building safer communities where you live, work, study and visit. Their long-term ambition is bold but simple: to make the United States of America the safest country in the world.Knightscope is a client of RedChip Companies. Visit RedChip.com to learn more.

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also advancing a near-term direct-to-consumer revenue opportunity in nutraceuticals, positioning the company as a transformative force in both pharmaceutical and consumer health markets.Jupiter Neurosciences is a client of RedChip. Visit www.redchip.com/stocks/JUNS to learn more.

Alliance Entertainment is the global leader in physical media distribution, acting as the crucial gateway between major content producers and retailers. The company partners with nearly every major film studio, music label, and video game maker, including Disney, Sony, Universal, Warner Bros., Universal Music, Sony Music, Warner Music, Microsoft, and Nintendo, to distribute their products to retailers worldwide. With over 325,000 in stock SKUs, Alliance supplies major retailers like Walmart, Amazon, and Best Buy, as well as thousands of independent stores. In fiscal 2024, Alliance generated over $1.1 billion in revenue, with more than $250 million from exclusive distribution deals. As the dominant force in the physical media market, Alliance's unmatched scale and reach secure its leadership position. Looking ahead, the company remains committed to fueling its growth through strategic acquisitions, leveraging its proven ability to expand and strengthen its portfolio in an evolving industry.Alliance Entertainment is a client of RedChip. Visit RedChip.com to learn more.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.Calidi Biotherapeutics is a client of RedChip. Visit www.redchip.com/stocks/cldi to learn more.

60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60P is a client of RedChip. Visit www.redchip.com/stocks/sxtp to learn more.

Venu Holding Corporation (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU’s campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery, Roth’s Seafood and Chophouse, and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU’s upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU’s vision of redefining the live entertainment experience. VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape. Visit www.redchip.com/stocks/VENU to learn more. Venu Holding Corp. (VENU) is a client of RedChip Companies, Inc. VENU agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in January 2025, and 10,000 shares of VENU Rule 144 stock, for six months of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. VENU also agreed to pay RedChip a $90,000 fee for a four-week national TV ad campaign aired weekdays from January 13 to February 7, 2025. Read our full disclosures at: www.redchip.com/legal/disclosures

ASP Isotopes (Nasdaq: ASPI) is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. Visit www.redchip.com/stocks/ASPI to learn more. ASP Isotopes (ASPI) agreed to pay RedChip Companies, Inc., a $12,500 monthly cash fee and $50,000 of Rule 144 stock, deemed earned immediately after the IPO, beginning in August 2022, for 12 months of RedChip investor awareness services. ASPI also agreed to pay RedChip a $50,000 fee for a national TV ad campaign aired May 10 to May 24, 2024. As of September 2024, RedChip’s shares of ASPI are unrestricted and RedChip intends to sell all of its shares immediately and you may be buying as RedChip is selling. As of November 1, 2024, RedChip has sold all of its ASPI shares. Read our full disclosures at: www.redchip.com/legal/disclosures

Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Diseases such as osteoarthritis, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”. Visit redchip.com/stocks/ENLV to learn more. Enlivex Therapeutics (ENLV) is a client of RedChip Companies, Inc. ENLV agreed to pay RedChip Companies, Inc. an $8,000 monthly cash fee, beginning in February 2024, plus 25,000 warrants with an exercise price of $3.25 and 25,000 warrants with an exercise price of $4.25, for six month of investor awareness services. All warrants have a term of three years from date of issuance. ENLV also agreed to pay RedChip a one-time $50,000 fee for a national TV ad campaign aired September 11 to September 25, 2024, a one-time $37,500 fee for a national TV ad campaign aired October 14 to October 25, 2024, and a one-time $37,500 fee for a national TV ad campaign aired December 4 to December 17, 2024. Read our full disclosures at: www.redchip.com/legal/disclosures

Gorilla Technology Group (Nasdaq: GRRR) is a global leader in AI-based IIOT (Industrial Internet of Things) solutions with a strong emphasis on security convergence, video analytics, and big data. Leveraging over 22 years of innovation and industry expertise, Gorilla provides transformative solutions that enhance the safety, efficiency, and operational capabilities of smart cities, smart ports, smart buildings, and more. The company's proprietary technologies empower clients across both public and private sectors by offering predictive insights and robust network defense, driving the next wave of digital transformation. With a footprint spanning over seven countries and 29 granted patents globally, Gorilla Technology is well positioned to accelerate revenue growth as it creates secure, intelligent environments that address the complexities of modern urban life and industrial operations. Visit www.redchip.com/stocks/GRRR to learn more. Gorilla Technology (GRRR) is a client of RedChip Companies, Inc. GRRR agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in August 2024, and can earn up to 15,000 shares of Rule 144 stock, for six month of investor awareness services. RedChip intends to and will, if possible, sell all of its shares immediately upon removal of the restriction, and you may be buying as RedChip is selling. GRRR also paid RedChip a one-time cash fee of fifty-thousand dollars for a 10-day national TV ad campaign aired October 16-29, 2024. Read our full disclosures at: www.redchip.com/legal/disclosures